Related Experiment Video
Updated: Jun 26, 2026
05:57
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
Serum growth factor analysis in dry eye syndrome
Jay C Bradley1, Rachael H Bradley, David L McCartney
1Texas Tech University Health Sciences Center, Department of Ophthalmology & Visual Sciences, Lubbock, Texas 79430-7217, USA. docjayb@aol.com
Clinical & Experimental Ophthalmology
|January 9, 2009
Summary
This study found no significant difference in serum growth factor levels between dry eye syndrome patients and controls. Understanding these factors is crucial for autologous serum eye drop therapy in ocular surface diseases.
Area of Science:
- Ophthalmology
- Biochemistry
- Molecular Biology
Background:
- Dry eye syndrome (DES) is a prevalent ocular surface disease.
- Autologous serum eye drops (ASEDs) are increasingly used for refractory DES.
- The role of serum growth factors in DES and ASED efficacy requires investigation.
Purpose of the Study:
- To conduct a comprehensive analysis of serum growth factor profiles in DES patients.
- To compare these profiles with those of age- and gender-matched healthy controls.
- To inform the therapeutic application of ASEDs.
Main Methods:
- Recruitment of 6 DES patients and 6 matched controls.
- Collection and processing of whole blood to obtain serum.
- Quantification of multiple growth factors (e.g., TGF-β, NGF, IGF-1, EGF, FGF, VEGF, PDGF, BDNF) using ELISA.
- Statistical analysis employing the Mann-Whitney U-test with Bonferroni correction.
Main Results:
- No statistically significant differences were observed in the serum levels of quantified growth factors between DES patients and controls.
- A wide array of growth factors, including those involved in cell proliferation, differentiation, and inflammation, were measured.
Conclusions:
- Serum growth factor levels do not significantly differ between dry eye patients and controls.
- This comprehensive analysis provides baseline data for serum growth factor levels.
- Understanding these levels is important for optimizing ASED therapy in ocular surface diseases.
